Variagenics Inc., of Cambridge, Mass., said it received U.S. Patent No. 6,200,754 titled ¿Inhibitors of Alternative Alleles of Genes Encoding Products that Mediate Cell Response to Environmental Changes.¿ It covers technology Variagenics said is integral to its strategy of applying pharmacogenomics to the development of individualized drugs. The company also said it received U.S. Patent No. 6,218,120 titled ¿Methods for Detecting Human Methylenetetrahydrofolate Reductase Allelic Variants.¿
Vivus Inc., of Mountain View, Calif., said it received U.S. Patent No. 6,228,864 titled ¿Administration of 5-HT Receptor Agonists and Antagonists to Treat Premature Ejaculation.¿ It covers treatment claims for premature ejaculation by administration of 5-HT4 agonists alone or in combination with other agents.
Xanthon Inc., of Research Triangle Park, N.C., said it received U.S. Patent No. 6,180,346 B1 titled ¿Electropolymerizable Film and Method of Making and Use Thereof.¿ It is a continuation of Xanthon¿s U.S. Patent No. 5,871,918, and covers an electrode and a unique method for electropolymerizing a film onto a conductive working surface and covalently attaching a DNA probe to the film.